Literature DB >> 26835107

Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.

Nur A Rahmat1, Gregory Y H Lip1.   

Abstract

In the last decade, we have witnessed the emergence of the oral non-vitamin K oral anticoagulants (NOACs), which have numerous advantages compared with the vitamin K antagonists, particularly their lack of need for monitoring; as a result their use is increasing. Nonetheless, the NOACs face two major challenges: the need for reliable laboratory assays to assess their anticoagulation effect, and the lack of approved antidotes to reverse their action. This article provides an overview of monitoring the anticoagulant effect of NOACs and their potential specific antidotes in development.

Entities:  

Keywords:  Non-vitamin K oral anticoagulants (NOACs); anticoagulation; antidotes; atrial fibrillation; monitoring

Year:  2015        PMID: 26835107      PMCID: PMC4711499          DOI: 10.15420/aer.2015.04.02.90

Source DB:  PubMed          Journal:  Arrhythm Electrophysiol Rev        ISSN: 2050-3369


  46 in total

1.  Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

Authors:  T Baglin; A Hillarp; A Tripodi; I Elalamy; H Buller; W Ageno
Journal:  J Thromb Haemost       Date:  2013-01-24       Impact factor: 5.824

2.  Laboratory monitoring of the non-vitamin K oral anticoagulants.

Authors:  Andrew D Blann; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094

3.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2013-05       Impact factor: 5.214

4.  Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

Authors:  Anne Godier; Anastasia Miclot; Bernard Le Bonniec; Marion Durand; Anne-Marie Fischer; Joseph Emmerich; Catherine Marchand-Leroux; Thomas Lecompte; Charles-Marc Samama
Journal:  Anesthesiology       Date:  2012-01       Impact factor: 7.892

5.  A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.

Authors:  Alexander G G Turpie; Sylvia Haas; Reinhold Kreutz; Lorenzo G Mantovani; Cassandra W Pattanayak; Gerlind Holberg; Waheed Jamal; André Schmidt; Martin van Eickels; Michael R Lassen
Journal:  Thromb Haemost       Date:  2013-10-24       Impact factor: 5.249

6.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Authors:  Christian T Ruff; Robert P Giugliano; Elliott M Antman; Sharon E Crugnale; Tomas Bocanegra; Michele Mercuri; James Hanyok; Indravadan Patel; Minggao Shi; Dan Salazar; Carolyn H McCabe; Eugene Braunwald
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

7.  Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.

Authors:  A Hillarp; F Baghaei; I Fagerberg Blixter; K M Gustafsson; L Stigendal; M Sten-Linder; K Strandberg; T L Lindahl
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

8.  A specific antidote for dabigatran: functional and structural characterization.

Authors:  Felix Schiele; Joanne van Ryn; Keith Canada; Corey Newsome; Eliud Sepulveda; John Park; Herbert Nar; Tobias Litzenburger
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

Review 9.  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Authors:  Adam Cuker; Deborah M Siegal; Mark A Crowther; David A Garcia
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094

10.  The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.

Authors:  Greg Hapgood; Jenny Butler; Erica Malan; Sanjeev Chunilal; Huyen Tran
Journal:  Thromb Haemost       Date:  2013-06-20       Impact factor: 5.249

View more
  1 in total

1.  Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.

Authors:  Manuela Albisetti; Arno Schlosser; Martina Brueckmann; Savion Gropper; Stephan Glund; Igor Tartakovsky; Leonardo R Brandão; Paul A Reilly
Journal:  Res Pract Thromb Haemost       Date:  2017-11-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.